[admin]

Drug repurposing — the systematic search for new therapeutic uses among already-approved or clinically tested compounds — has emerged as one of the most resource-efficient strategies in oncology research. Unlike de novo drug discovery, which demands multi-million-compound libraries, specialized screening infrastructure, and lengthy development timelines, repurposing builds on compounds that carry established bioactivity, safety, and bioavailability profiles. TargetMol has positioned itself at the center of this shift, supplying curated, annotated, and quality-validated compound libraries purpose-built for drug repurposing workflows across multiple cancer research areas.

Why Drug Repurposing Matters for Oncology Research

The conventional path to an oncology drug is costly and failure-prone. De novo screening against uncharacterized compounds carries compounding uncertainties at every stage — from initial hit identification through preclinical toxicology to clinical attrition. Repurposing shrinks several of those unknowns at once. Approved drugs have survived regulatory review; clinical-phase drugs have accumulated at least early-stage human safety data. For oncology researchers, this translates into a faster, more cost-effective route toward identifying compounds that affect tumor cell metabolism, growth, invasion, and metastasis.

TargetMol’s strategic insight is that the availability of well-annotated, ready-to-screen approved and clinical compound libraries directly addresses this industry pain point, enabling research teams to run high throughput screening (HTS) and high content screening (HCS) workflows against collections where compound behavior is already partially characterized.

TargetMol’s Core Repurposing Libraries for Oncology

Approved and Clinical Drug Collections

The L9200 Drug Repurposing Compound Library stands as one of TargetMol’s most comprehensive tools for repositioning work. It assembles 5,745 approved and clinical drugs — compounds approved by the FDA, EMA, or NMPA, or included in the USP, BP, EP, JP, or CP pharmacopeial dictionaries — into a single screening-ready collection. Cancer, cardiovascular disease, immunology, and respiratory system research are all represented, while pathway-level annotations covering targets such as 5-HT Receptor, Sodium Channel, p38 MAPK, PI3K, and MEK provide the context researchers need to design mechanistically informed screens.

For teams whose focus is specifically on FDA-cleared agents, the L4200 FDA-Approved Drug Library offers 2,073 FDA-approved drugs with documented structure, target, IC50 value, and biological activity descriptions. The library spans oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, and analgesia research areas, making it applicable to both pure tumor biology studies and translational programs exploring cancer comorbidities.

The L1000 Approved Drug Library broadens the approved-drug footprint further with 3,170 compounds approved by the FDA, EMA, or NMPA. Beyond standard repurposing screens, this library has a documented application in iPSC reprogramming: researchers have identified compounds within it that can functionally replace reprogramming transcription factors, enhance iPSC generation efficiency, and accelerate the reprogramming process — a capability relevant to cancer cell differentiation induction studies.

For research programs requiring clinical-stage rather than fully approved compounds, the L3400 Clinical Compound Library supplies 3,064 clinical-phase compounds categorized into Phase 1, Phase 2, and Phase 3, covering targets including JAK, EGFR, mTOR, CDK, HDAC, AKT, and PARP. The phase categorization allows teams to design stage-specific screening experiments and select compounds with a level of human safety evidence matched to their program’s requirements.

Anti-Cancer Compound Libraries

TargetMol maintains a dedicated anti-cancer product line built on the specific biological characteristics of tumor cells, including abnormal cell signaling, chromatin alterations, altered energy metabolism, and aberrant vascularization.

The L2100 Anti-Cancer Compound Library is the largest collection in this line, comprising 10,240 compounds selected for anti-tumor activity, with bioactivity and safety profiled in preclinical and clinical settings. Targets represented include PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, and others. Researchers investigating the molecular mechanisms of tumorigenesis or running large-scale anti-tumor drug screens will find this library particularly suited to both objectives.

For teams that require approved agents as positive controls or reference points in biological cancer investigation, the L2110 Anti-Cancer Approved Drug Library provides 2,020 FDA-, EMA-, or NMPA-approved anti-cancer drugs selected from published literature and databases. Disease area coverage includes lung cancer, breast cancer, leukemia, and lymphoma, among others, and the library carries the same target annotations — PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK — as the broader anti-cancer collection.

The L2150 Anti-Cancer Drug Library bridges approved and clinical sources with 3,755 compounds carrying demonstrated or potential anticancer activity, drawn from FDA-approved and clinical trial pools. This library is explicitly designed for anti-tumor drug repositioning drug discovery and spans 15 different cancer research areas, providing one of the widest single-collection oncology coverage options in TargetMol’s portfolio.

Annotation and Data Infrastructure Supporting Repurposing

A compound library is only as useful as the information available to interpret screening results. Across its libraries, TargetMol provides compound-level documentation that typically includes molecular structure, target identification, activity data, IC50 values, and biological activity descriptions. This annotation density reduces the post-screen interpretation burden and accelerates the step from initial hit to mechanistic hypothesis.

For larger umbrella collections, the L4000 Bioactive Compound Library — aggregating more than 19,730 small molecule compounds with known biological activities and clear targets — encompasses the Clinical Compound Library (L3400), a preclinical compound library (L3410), and the Approved Drug Library (L1000) within a single portfolio. Disease area coverage extends across cancer, metabolism, immunology, and cardiovascular disease, supporting multidisciplinary research programs that sit at the intersection of oncology and systemic disease biology.

Quality Validation Standards

Across the compound library portfolio, TargetMol applies NMR, HPLC, and LCMS validation to confirm compound structure and purity. This multi-technique approach to quality assurance is cited consistently across the approved drug, clinical, anti-cancer, and specialty collections. By ensuring that each compound delivered to the researcher is structurally accurate and meets purity thresholds, TargetMol reduces the rate of false positives and false negatives attributable to compound quality issues — a persistent concern in large-scale screening programs.

Structural and Physicochemical Profile for Cellular Assay Compatibility

Across the oncology-relevant collections, TargetMol characterizes its compound sets as structurally diverse, medicinally active, and cell permeable. Cell permeability is a non-trivial prerequisite for any cell-based oncology assay, and its consistent inclusion as a selection criterion across the library portfolio means that researchers using these collections in cellular HTS or HCS workflows are working with compounds selected to function in that biological context, not merely in biochemical assays.

A Coherent System for Oncology Drug Repurposing

For oncology research teams seeking to accelerate hit identification through drug repurposing, TargetMol’s compound library portfolio provides a layered set of options: broad approved-drug collections for wide-net repositioning screens, dedicated anti-cancer collections for tumor-biology-focused programs, clinical-stage libraries for stage-stratified analyses, and a large annotated bioactive collection for mechanism interrogation. The shared infrastructure of validated purity, compound-level annotation, and cellular compatibility across these libraries enables research teams to select the collection that best matches their disease focus, target class, and screening scale — without rebuilding the compound characterization work from scratch.

http://www.targetmol.com
TargetMol Chemicals Inc.

[Author]

Posts